Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Randox Licenses sPLA2 CVD Risk Test from Aterovax

Published: Thursday, May 02, 2013
Last Updated: Wednesday, May 01, 2013
Bookmark and Share
Partnership to develop Aterovax’s patented biomarker sPLA2 for the assessment of cardiovascular risk.

Randox Laboratories Ltd. and Aterovax SA have announced a strategic partnership to commercialize Aterovax’s patented biomarker secreted Phospholipase A2 (sPLA2) for the assessment of cardiovascular risk. Terms of the alliance were not disclosed.

sPLA2 is a novel biomarker that independently and over and above traditional risk factors predicts adverse outcomes in patients with stable coronary artery disease and is useful in the risk stratification of patients with acute coronary syndrome.

Randox have exclusive rights to develop, manufacture and market the new test for use on automated immunoassay analyzers and will develop the sPLA2 test for its own range of analyzers and other diagnostic analyzers.

Dr. Peter FitzGerald CBE FREng, Managing Director at Randox commented “this was an exciting opportunity for Randox to expand its portfolio of CVD biomarkers and demonstrates continued investment in this field. The new SPLA2 test has been shown to add significant clinical value when combined with other biomarkers in the Randox range of tests and offers us the opportunity to provide an effective panel of tests for CVD risk assessment with strong clinical utility. The sPLA2 test will be offered to hospital laboratories through our global distribution network in 145 countries.”

Dr. Gerald Ulrich, CEO of Aterovax believes this strategic partnership will utilize the strengths of Aterovax’s many years research in CVD, especially on the development, role and clinical utility of its patented biomarker (sPLA2) in CVD risk assessment/patient stratification with Randox’s expertise in developing assays for automated immunoassay platforms and “pioneering” novel new assays in CVD biomarkers to establish a sustainable market presence for sPLA2 in the global clinical laboratory market for CVD risk assessment.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Tumor Markers Reveal Lethality Of Bladder Cancers
Researchers found that detection of certain tumor cells in early stage cancers helps identify high-risk cancers.
Preventing "Friendly Fire" in the Pancreas
Researchers inhibit process that leads to the body attacking its own insulin-producing cells.
Drug Target for Triple-Negative Breast Cancer Found
A team of researchers led by UC San Francisco scientists has identified a new drug target for triple-negative breast cancer.
Smartphone Laboratory Detects Cancer
Researchers develop low-cost, portable laboratory on a smartphonecapable of analysing multiple samples simultaneously.
First Entirely 3D-printed Organ-on-a-Chip with Integrated Sensors
New approach to manufacturing may allow researchers to rapidly design organs-on-chips that match the properties of a specific disease or individual patient's cells.
Bacterial Genes Boost Current in Human Cells
Borrowing and tweaking bacterial genes to enhance electrical activity might treat heart, nervous system injury.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
Untangling a Cause of Memory Loss in Neurodegenerative Diseases
The mouse study identifies a possible therapeutic target for a family of disorders.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos